Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare disorder characterized by gradually increasing sensory loss and weakness associated with loss of reflexes. This is caused by an autoimmune process in which the body’s own immune system doesn’t recognize its nerve fibers and attacks them. This leads to inflammation of nerve roots and peripheral nerves, as well as the deterioration of the fatty protective covering (myelin sheath) over the nerves, affecting how fast the nerve signals are transmitted and leading to loss of nerve fibers.1,2
CIDP is considered a rare disease, with the number of new cases per year averaging about 1-2 per 100,000 people, while the prevalence reflecting the accumulation of cases over time is estimated to be 5-9 per 100,000.1
CIDP is often difficult to diagnose because it is so rare. If a health care provider suspects CIDP, they may perform the following tests to confirm a diagnosis.2,3
The chief symptoms of CIDP are progressive, symmetric weakness of both muscles around the hip and shoulder as well as of the hands and feet. This pattern of weakness is highly suggestive of CIDP.
Other signs and symptoms of CIDP can include:2
The primary goals of treatment for CIDP are to reduce symptoms in order to improve functional status and if possible, maintain long-term remission. Initial treatment options include corticosteroids, therapeutic plasma exchange, and immunoglobulin replacement therapy given by intravenous or subcutaneous administration.4
The term “immunoglobulin” (Ig) refers to the component of blood plasma that contains antibodies. Ig replacement therapy works in several ways to treat CIDP, including inhibiting the pathogenic antibody effects that cause CIDP. This results in reduction of the progression of the disease, and improvement in symptoms.4,5
IVIg is given through a vein over the course of several hours. Newer preparations of higher concentrations that can be given subcutaneously have been tested in controlled trials in CIDP patients. This includes subcutaneous immunoglobulin (Hizentra®) which is indicated for the treatment of adult patients with CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
Learn more about the differences between IVIg and SCIg
Chronic Inflammatory Demyelinating Polyneuropathy: Considerations for Diagnosis, Management, and Population Health
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Subcutaneous Immunoglobulin Treatment in CIDP and MMN. Efficacy, Treatment Satisfaction and Costs
Get a quick overview of the Freedom Infusion System, the benefits of SCIg with Freedom and how to prevent adverse effects with the proper ancillary supplies.
Use this tool to help walk you through your SubQ infusions with the FREEDOM60®.
Download Spanish Version
Use this tool to help walk you through your SubQ infusions with the FreedomEdge®.
The GBS|CIDP Foundation International supports individuals and their families affected by Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related syndromes.
Join the immune globulin community with access to IG Living magazine, advocacy groups, expert opinions, and patients with rare diseases.